REGULATED INFORMATION

GHENT, Belgium, 14 August 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Abingworth Management Limited and Abingworth LLP.

Abingworth Management Limited notified Ablynx that they have dropped below the 5% threshold and now hold 2,718,908 Ablynx shares, which represent 4.99% of the current 54,512,424 outstanding Ablynx shares. Abingworth LLP holds 615,644 Ablynx shares, representing 1.13% of the current outstanding Ablynx shares. The combined holding of Abingworth Management Limited and Abingworth LLP is now 3,334,552 Ablynx shares, which represents 6.12% of the current 54,512,424 outstanding Ablynx shares.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors:
http://www.ablynx.com/investors/share-information/major-shareholders/.

About Ablynx

Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the development of Nanobodies®:
http://www.ablynx.com/technology-innovation/understanding-nanobodies/, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes:
http://www.ablynx.com/rd-portfolio/overview/ in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com:
http://www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com:
mailto:marieke.vermeersch@ablynx.com%20
Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t:   +44 (0)20 7866 7905
e:  ablynx@instinctif.com:
mailto:ablynx@instinctif.com

Jim Rusagara
Brussels office
t:   +32 (0)2 626 9500
e:  ablynx@instinctif.com :
mailto:ablynx@instinctif.com%20


pdf format of the press release:
http://hugin.info/137912/R/1945422/705332.pdf



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1945422